Targeting a specific mutation in lung cancer to improve radiation therapy outcomes
Project 3: Targeting KEAP1-Mediated Radioresistance in Lung Cancer
This study is looking at how to make radiation therapy work better for people with non-small cell lung cancer by tailoring the treatment to their specific genetic changes, especially focusing on those with certain mutations, to see if blocking a specific enzyme can help their tumors respond better to radiation and lower the chances of the cancer coming back.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10914188 on NIH RePORTER |
What this research studies
This research focuses on improving radiation therapy for patients with non-small cell lung cancer (NSCLC) by personalizing treatment based on genetic mutations. Specifically, it investigates how inhibiting glutaminase can make tumors with KEAP1 or NFE2L2 mutations more sensitive to radiation. The study aims to determine if this targeted approach can reduce local recurrence rates in these patients. By utilizing molecular biomarkers, the research seeks to develop a more effective treatment strategy for those affected by this type of lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have KEAP1 or NFE2L2 mutations.
Not a fit: Patients with wildtype NSCLC or those without the specific mutations being targeted may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective radiation treatments for lung cancer patients with specific genetic mutations, potentially improving their survival rates.
How similar studies have performed: Previous research has shown mixed results regarding glutaminase inhibition in radiosensitizing NSCLC, making this approach both novel and potentially impactful.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Diehn, Maximilian — Stanford University
- Study coordinator: Diehn, Maximilian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.